BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $874,564 | +11.0% | 12,848 | +33.1% | 0.03% | +3.8% |
| Q2 2023 | $787,730 | +167859.5% | 9,650 | +52.4% | 0.03% | +73.3% |
| Q1 2023 | $469 | +93.8% | 6,334 | +117.1% | 0.02% | +50.0% |
| Q4 2022 | $242 | -100.0% | 2,917 | -29.5% | 0.01% | -47.4% |
| Q3 2022 | $1,175,000 | -46.0% | 4,137 | -34.1% | 0.02% | -61.2% |
| Q2 2022 | $2,176,000 | -26.1% | 6,277 | -7.7% | 0.05% | +75.0% |
| Q1 2022 | $2,944,000 | +207.9% | 6,798 | +267.7% | 0.03% | +64.7% |
| Q4 2021 | $956,000 | +65.4% | 1,849 | +55.0% | 0.02% | +13.3% |
| Q3 2021 | $578,000 | -78.9% | 1,193 | -80.3% | 0.02% | -78.9% |
| Q2 2021 | $2,733,000 | +490.3% | 6,070 | +401.2% | 0.07% | +787.5% |
| Q1 2021 | $463,000 | -30.0% | 1,211 | -41.8% | 0.01% | -60.0% |
| Q4 2020 | $661,000 | +16.2% | 2,082 | -9.4% | 0.02% | +233.3% |
| Q3 2020 | $569,000 | -77.7% | 2,298 | -76.2% | 0.01% | -94.3% |
| Q2 2020 | $2,553,000 | +1014.8% | 9,669 | +701.1% | 0.10% | +650.0% |
| Q1 2020 | $229,000 | -45.3% | 1,207 | -36.8% | 0.01% | -60.0% |
| Q4 2019 | $419,000 | +88.7% | 1,911 | +68.8% | 0.04% | +133.3% |
| Q3 2019 | $222,000 | -43.8% | 1,132 | -40.3% | 0.02% | -44.4% |
| Q2 2019 | $395,000 | +43.6% | 1,896 | +37.1% | 0.03% | +58.8% |
| Q1 2019 | $275,000 | +1045.8% | 1,383 | +728.1% | 0.02% | +750.0% |
| Q4 2018 | $24,000 | -97.5% | 167 | -96.5% | 0.00% | -97.2% |
| Q3 2018 | $962,000 | +80.5% | 4,711 | +30.7% | 0.07% | +136.7% |
| Q2 2018 | $533,000 | +6.8% | 3,604 | +9.0% | 0.03% | -30.2% |
| Q1 2018 | $499,000 | +841.5% | 3,305 | +716.0% | 0.04% | +514.3% |
| Q4 2017 | $53,000 | +130.4% | 405 | +116.6% | 0.01% | +250.0% |
| Q3 2017 | $23,000 | -50.0% | 187 | -52.1% | 0.00% | -60.0% |
| Q2 2017 | $46,000 | +155.6% | 390 | +116.7% | 0.01% | +150.0% |
| Q1 2017 | $18,000 | -28.0% | 180 | -26.2% | 0.00% | -33.3% |
| Q4 2016 | $25,000 | -74.5% | 244 | -72.6% | 0.00% | -70.0% |
| Q3 2016 | $98,000 | +3166.7% | 891 | +2774.2% | 0.01% | – |
| Q2 2016 | $3,000 | -91.2% | 31 | -91.8% | 0.00% | -100.0% |
| Q4 2015 | $34,000 | -52.1% | 379 | -50.4% | 0.01% | -14.3% |
| Q3 2015 | $71,000 | -77.0% | 764 | -77.1% | 0.01% | -76.7% |
| Q4 2014 | $309,000 | – | 3,339 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |